Siblings 圖書 [1/1] 期刊論文 [328/331] Collection Statistics 近3年內發表的文件:16(8.94%) 含全文筆數:115(64.25%) 文件下載次數統計 下載大於0次:115(100.00%) 下載大於100次:112(97.39%) 檔案下載總次數:39419(22.08%) 最後更新時間: 2024-12-03 22:16 Top Upload Loading... Top Download Loading... Recent Submissions Single-cell RNA sequencing via Endo... Nivolumab plus ipilimumab (N plus I... Risk of type 2 diabetes mellitus an... Phase 1 studies of D07001-F4 and D0... Updated overall survival (OS) from ... Outcomes of post-immunotherapy dura... Updated overall survival (OS) from ... Updated results of the FOENIX-CCA2 ... Comparative genomic analysis and it... A phase II trial of nivolumab, gemc...

Jump to a point in the index: (Choose year) 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009 2008 2007 2006 2005 2004 2003 2002 2001 2000 1999 1998 1997 1996 1995 1994 1993 1992 1991 1990 1985 1980 1975 1970 1960 1950 (Choose month) January February March April May June July August September October November December Or type in a year:

Ordering With Most Recent First Show Oldest First

Showing items 61-70 of 179. (18 Page(s) Totally) << < 2 3 4 5 6 7 8 9 10 11 > >> View [10|25|50] records per page

Date	Title	Relation
2018-02	Nivolumab safety profile in Asian and Western patients with chemotherapy-refractory (CTx-R) advanced gastric/gastroesophageal junction (adv G/GEJ) cancer from the ATTRACTION-2 and CheckMate-032 trials	Journal of Clinical Oncology. 2018 Feb;36(4, Suppl.):Abstract number 90.
2018-02	Dose modifications of liposomal irinotecan (nal-IRI)+5-fluorouracil/leucovorin (5-FU/LV) in NAPOLI-1: Impact on efficacy	Journal of Clinical Oncology. 2018 Feb;36(4, Suppl.):388.
2018-02	Subgroup analysis by baseline pain intensity (BPI) and analgesic use (BAU) in NAPOLI-1: A phase III study of liposomal irinotecan (nal IRI)+/- 5-fluorouracil/leucovorin (5-FU/LV) in patients (pts) with metastatic pancreatic ductal adenocarcinoma (mPDAC) p	Journal of Clinical Oncology. 2018 Feb;36(4, Suppl.):379.
2018-02	Subgroup analysis by baseline (BL) weight-associated parameters: A phase III study of liposomal irinotecan (nal-IRI)+/--5fluorouracil/leucovorin (5-FU/LV) in patients (pts) with metastatic pancreatic ductal adenocarcinoma (mPDAC) previously treated with g	Journal of Clinical Oncology. 2018 Feb;36(4, Suppl.):410.
2018-01	Role of academic institute in cancer therapy development in National Institute of Cancer Research, NHRI in Taiwan	Cancer Science. 2018 Jan;109(Suppl. 1):43.
2018-01	Environmental tobacco smoke and risk of pancreatic cancer among never smokers	Cancer Science. 2018 Jan;109(Suppl. 1):769.
2018-01	The role of aberrant mitochondrial phosphoenolpyruvate carboxykinase expression in pancreatic neuroendocrine tumors	Cancer Science. 2018 Jan;109(Suppl. 1):466.
2017-11	Subgroup analysis by prior non-liposomal irinotecan therapy in NAPOLI-1: A phase 3 study of nal-IRI65-fluorouracil/leucovorin in patients with metastatic pancreatic ductal adenocarcinoma previously treated with gemcitabine-based therapy	Annals of Oncology. 2017 Nov;28(Suppl. 10):67-U261.
2017-11	CA19-9 decrease and overall survival (OS) in the NAPOLI-1 trial of liposomal irinotecan (nal-IRI) � 5-fluorouracil and leucovorin (5-FU/LV) in metastatic pancreatic ductal adenocarcinoma (mPDAC) previously treated with gemcitabine-based therapy	Annals of Oncology. 2017 Nov;28(Suppl. 10):Meeting Abstract 227P.
2017-09	ATTRACTION-04 (ONO-4538-37): A randomized, multicenter, phase 2/3 study of nivolumab (Nivo) plus chemotherapy in patients (Pts) with previously untreated advanced or recurrent gastric (G) or gastroesophageal junction (GEJ) cancer	Annals of Oncology. 2017 Sep;28(Suppl. 5):Meeting Abstract 777TiP.

Showing items 61-70 of 179. (18 Page(s) Totally) << < 2 3 4 5 6 7 8 9 10 11 > >> View [10|25|50] records per page